Cargando…
Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA
Vancomycin is the treatment of choice for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Clinically, combinations of vancomycin (VAN) and beta-lactams have been shown to improve patient outcomes compared to VAN alone for the treatment of MRSA bloodstream infections. However...
Autores principales: | Bhise, Ketki, Sau, Samaresh, Kebriaei, Razieh, Rice, Seth A., Stamper, Kyle C., Alsaab, Hashem O., Rybak, Michael J., Iyer, Arun K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073369/ https://www.ncbi.nlm.nih.gov/pubmed/30036944 http://dx.doi.org/10.3390/ma11071245 |
Ejemplares similares
-
2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
por: Kebriaei, Razieh, et al.
Publicado: (2018) -
1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019) -
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
por: Sau, Samaresh, et al.
Publicado: (2019) -
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020) -
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)